Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Xiongxiong Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7594-0329; OpenAlex author ID A5052313585. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers

Papers 18

  1. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian rando… Co-author DOI 10.1016/j.lanwpc.2022.100596↗
  2. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  3. Aberrant human ClpP activation disturbs mitochondrial proteome homeostasis to suppress pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.chembiol.2022.07.002↗
  4. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  5. PIWIL1 interacting RNA piR-017061 inhibits pancreatic cancer growth via regulating EFNA5. Last author DOI 10.1007/s13577-020-00463-2↗
  6. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  7. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.682261↗
  8. Construction and integrated analysis of a lncRNA-associated competing endogenous RNA network reveal functional lncRNAs in pancreatic cancer. Last author DOI 10.21037/tcr.2020.04.03↗
  9. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  10. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Co-author DOI 10.2147/ott.s223221↗
  11. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0965-3↗
  12. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  13. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.16732↗
  14. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. First author DOI 10.18632/oncotarget.7375↗
  15. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. Co-author DOI 10.3109/07357907.2015.1025794↗
  16. A case-control study indicates that the TRIB1 gene is associated with pancreatic cancer. Co-author DOI 10.4238/2014.august.7.30↗
  17. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Co-author DOI 10.1007/s00441-013-1711-x↗
  18. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 11 shared papers, 2013–2023 · strength 0.85
  2. Chenghong Peng · 12 shared papers, 2013–2023 · strength 0.81
  3. Chenlei Wen · 8 shared papers, 2016–2023 · strength 0.76
  4. Xiaxing Deng · 8 shared papers, 2013–2023 · strength 0.73
  5. Hao Chen · 9 shared papers, 2013–2022 · strength 0.66
  6. Xinjing Wang · 7 shared papers, 2016–2022 · strength 0.60
  7. Xiaomei Tang · 6 shared papers, 2016–2021 · strength 0.46
  8. Yuan Fang · 8 shared papers, 2013–2019 · strength 0.44
  9. Qian Zhan · 6 shared papers, 2013–2022 · strength 0.43
  10. Siyi Zou · 3 shared papers, 2021–2023 · strength 0.37
  11. Jiabin Jin · 5 shared papers, 2013–2023 · strength 0.33
  12. Zhen Huo · 4 shared papers, 2017–2020 · strength 0.32
  13. Xiaxing Deng · 5 shared papers, 2013–2020 · strength 0.31
  14. Hongzhe Li · 4 shared papers, 2017–2021 · strength 0.31
  15. Baiyong Shen · 3 shared papers, 2016–2023 · strength 0.24
  16. Weishen Wang · 2 shared papers, 2020–2021 · strength 0.23
  17. Yangbing Jin · 2 shared papers, 2021–2023 · strength 0.22
  18. Henghui Zhang · 2 shared papers, 2021–2023 · strength 0.22
  19. Dongfeng Cheng · 2 shared papers, 2021–2023 · strength 0.22
  20. Jiancheng Wang · 2 shared papers, 2021–2023 · strength 0.22
  21. Shuyu Zhai · 2 shared papers, 2019–2020 · strength 0.22
  22. Yuanbin Liu · 2 shared papers, 2019–2020 · strength 0.22
  23. Hao Qian · 2 shared papers, 2019–2021 · strength 0.21
  24. Jing Xie · 2 shared papers, 2017–2021 · strength 0.20
  25. Lu Zhou · 2 shared papers, 2019–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.